Liver toxicity and pioglitazone: Data are missing

BMJ

Volumn 329, Issue 7471, 2004, Pages 918-

  Amin, Peshraw ^a  

^a DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

HUMAN; LETTER; LIVER FAILURE; LIVER FUNCTION TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; CHEMICALLY INDUCED DISORDER; LIVER DISEASE; NOTE;

HUMANS; HYPOGLYCEMIC AGENTS; LIVER DISEASES; THIAZOLIDINEDIONES;

EID: 7044227435     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.329.7471.918     Document Type: Letter

References (3)

1. Farley-Hills E, Sivasankar R, Martin M. Fatal liver failure associated with pioglitazone. BMJ 2004; 329: 429. (21 August.)
2. Isley WL. Hepatoxicity of thiozolidinediones. Expert Opin Drug Saf 2003; 2(6): 581–6.
3. National Institute for Clinical Excellence. Guidance on the use of glitazones for the treatment of type 2 diabetes London: NICE, 2003. (Technology Appraisal 63.)